EphB4 provides survival advantage to squamous cell carcinoma of the head and neck
書誌事項
- 公開日
- 2006-04-13
- 権利情報
-
- http://onlinelibrary.wiley.com/termsAndConditions#vor
- DOI
-
- 10.1002/ijc.21926
- 公開者
- Wiley
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:p>The receptor tyrosine kinase EphB4 and its ligand EphrinB2 play critical roles in blood vessel maturation, and are frequently overexpressed in a wide variety of cancers. We studied the aberrant expression and biological role of EphB4 in head and neck squamous cell carcinoma (HNSCC). We tested the effect of EphB4‐specific siRNA and antisense oligonucleotides (AS‐ODN) on cell growth, migration and invasion, and the effect of EphB4 AS‐ODN on tumor growth <jats:italic>in vivo</jats:italic>. All HNSCC tumor samples express EphB4 and levels of expression correlate directly with higher stage and lymph node metastasis. Six of 7 (86%) HNSCC cell lines express EphB4, which is induced either by EGFR activation or by <jats:italic>EPHB4</jats:italic> gene amplification. EphrinB2 was expressed in 65% tumors and 5 of 7 (71%) cell lines. EphB4 provides survival advantage to tumor cells in that EphB4 siRNA and AS‐ODN significantly inhibit tumor cell viability, induce apoptosis, activate caspase‐8, and sensitize cells to TRAIL‐induced cell death. Furthermore, EphB4‐specific AS‐ODN significantly inhibits the growth of HNSCC tumor xenografts <jats:italic>in vivo</jats:italic>. Expression of EphB4 in HNSCC tumor cells confers survival and invasive properties, and thereby provides a strong rationale for targeting EphB4 as novel therapy for HNSCC. © 2006 Wiley‐Liss, Inc.</jats:p>
収録刊行物
-
- International Journal of Cancer
-
International Journal of Cancer 119 (6), 1236-1248, 2006-04-13
Wiley
